NASDAQ:OMGA Omega Therapeutics (OMGA) Stock Price, News & Analysis $1.04 +0.14 (+15.56%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Omega Therapeutics Stock (NASDAQ:OMGA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Omega Therapeutics alerts:Sign Up Key Stats Today's Range$0.89▼$1.0650-Day Range$0.89▼$1.5852-Week Range$0.89▼$6.30Volume528,751 shsAverage Volume916,243 shsMarket Capitalization$57.36 millionP/E RatioN/ADividend YieldN/APrice Target$10.20Consensus RatingBuy Company OverviewOmega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More… Massive shakeup in defense contracting (Ad)There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.You need to check out the full story right here. Omega Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks66th Percentile Overall ScoreOMGA MarketRank™: Omega Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 400th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOmega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmega Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Omega Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Omega Therapeutics are expected to grow in the coming year, from ($1.23) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omega Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omega Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmega Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Omega Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.43% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 27.2, which indicates bearish sentiment.Change versus previous monthShort interest in Omega Therapeutics has recently decreased by 0.18%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmega Therapeutics does not currently pay a dividend.Dividend GrowthOmega Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.43% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 27.2, which indicates bearish sentiment.Change versus previous monthShort interest in Omega Therapeutics has recently decreased by 0.18%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentOmega Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Omega Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for OMGA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Omega Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omega Therapeutics' insider trading history. Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OMGA Stock News HeadlinesOmega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific MeetingsOctober 15 at 8:00 AM | globenewswire.comOmega Therapeutics Appoints New DirectorOctober 6, 2024 | investing.comUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!October 17, 2024 | Darwin (Ad)Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature CommunicationsSeptember 17, 2024 | globenewswire.comOmega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of ResearchAugust 14, 2024 | globenewswire.comOmega Therapeutics (NASDAQ:OMGA) Stock Quotes, Forecast and News SummaryAugust 8, 2024 | benzinga.comOmega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company ProgressAugust 6, 2024 | globenewswire.comOmega Therapeutics Announces Election of Richard N. Kender to Board of DirectorsJune 24, 2024 | globenewswire.comSee More Headlines OMGA Stock Analysis - Frequently Asked Questions How have OMGA shares performed this year? Omega Therapeutics' stock was trading at $3.01 at the start of the year. Since then, OMGA stock has decreased by 65.4% and is now trading at $1.04. View the best growth stocks for 2024 here. How were Omega Therapeutics' earnings last quarter? Omega Therapeutics, Inc. (NASDAQ:OMGA) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The business had revenue of $2.13 million for the quarter, compared to analyst estimates of $1.25 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 156.48% and a negative net margin of 1,249.54%. When did Omega Therapeutics IPO? Omega Therapeutics (OMGA) raised $126 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Who are Omega Therapeutics' major shareholders? Top institutional investors of Omega Therapeutics include Green Alpha Advisors LLC (0.11%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young. View institutional ownership trends. How do I buy shares of Omega Therapeutics? Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Omega Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omega Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OMGA CUSIPN/A CIK1850838 Webwww.omegatherapeutics.com Phone617-949-4360FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$10.20 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+880.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,430,000.00 Net Margins-1,249.54% Pretax Margin-1,249.54% Return on Equity-156.48% Return on Assets-40.77% Debt Debt-to-Equity Ratio0.49 Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$6.31 million Price / Sales9.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book0.99Miscellaneous Outstanding Shares55,155,000Free Float50,467,000Market Cap$57.36 million OptionableOptionable Beta1.84 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OMGA) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omega Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.